These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37994801)

  • 1. Hot-Spot Residue-Based Virtual Screening of Novel Selective Estrogen-Receptor Degraders for Breast Cancer Treatment.
    Dai R; Bao X; Zhang Y; Huang Y; Zhu H; Yang K; Wang B; Wen H; Li W; Liu J
    J Chem Inf Model; 2023 Dec; 63(23):7588-7602. PubMed ID: 37994801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
    Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
    J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
    Wang L; Sharma A
    ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
    Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
    Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
    Elife; 2022 May; 11():. PubMed ID: 35575456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
    Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
    Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
    Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
    Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug discovery of N-methyl-pyrazole derivatives as potent selective estrogen receptor degrader (SERD) for the treatment of breast cancer.
    Dai R; Bao X; Liu C; Yin X; Zhu Z; Zheng Z; Wang B; Yang K; Wen H; Li W; Zhu H; Du Q; Liu J
    Eur J Med Chem; 2024 Dec; 279():116894. PubMed ID: 39357315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
    Hu B; Hu J
    Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.
    Hu Z; Li Y; Xie B; Ning W; Xiao Y; Huang Y; Zhao C; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2019 Nov; 182():111605. PubMed ID: 31437778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
    Liang JJ; Yu WL; Yang L; Xie BH; Qin KM; Yin YP; Yan JJ; Gong S; Liu TY; Zhou HB; Hong K
    Eur J Med Chem; 2022 Feb; 229():114081. PubMed ID: 34992039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Thieno[2,3-
    Lu Z; Cao Y; Zhang D; Meng X; Guo B; Kong D; Yang Y
    J Med Chem; 2022 Apr; 65(7):5724-5750. PubMed ID: 35357160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
    Wardell SE; Marks JR; McDonnell DP
    Biochem Pharmacol; 2011 Jul; 82(2):122-30. PubMed ID: 21501600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
    Wittmann BM; Sherk A; McDonnell DP
    Cancer Res; 2007 Oct; 67(19):9549-60. PubMed ID: 17909066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
    Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
    Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
    Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Estrogenic Activity of Classical Estrogen Receptor-Binding Compounds.
    Pepermans RA; Prossnitz ER
    Methods Mol Biol; 2022; 2418():187-201. PubMed ID: 35119667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.